Accenture (NYSE: ACN) has acquired Bionest, a strategy and consulting firm dedicated to addressing complex strategic decisions for leading biopharma organizations across innovative areas of science including precision medicine and diagnostics, oncology, cell & gene therapy (CGT), and rare diseases. Headquartered in New York with a European office in Paris, Bionest’s team of 46 scientifically-minded consultants, industry executives, and specialists will join Accenture Strategy in the Life Sciences practice. Bionest’s focus on go-to-market strategy in life science’s most exciting and challenging areas will broaden and deepen Accenture’s capabilities.
Read the full article: Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest //
Source: https://www.businesswire.com/news/home/20230201006099/en/Accenture-Expands-Strategy-Capabilities-in-Life-Sciences-with-the-Acquisition-of-Bionest